Welcome to our dedicated page for Global Innovative Platforms news (Ticker: GIPL), a resource for investors and traders seeking the latest updates and insights on Global Innovative Platforms stock.
Global Innovative Platforms Inc. develops breath-based veterinary diagnostic technology focused on early detection of canine heartworm disease. Company updates for GIPL center on non-invasive breath analysis, research using heartworm-positive and heartworm-negative canine samples, and validation work tied to a potential point-of-care diagnostic approach.
The company’s disclosures also reference VOCAM Plus technology, artificial-intelligence and multivariate statistical analysis of breath data, and support arrangements for evaluation of its diagnostic system in animal health settings.
Global Innovative Platforms (OTC: GIPL) completed the first phase of a breath-based diagnostic study for early detection of heartworm in dogs on Oct 7, 2025. The 12-month project collected and analyzed over 100 breath samples to validate markers that could enable a point-of-care, non-invasive test able to identify infection earlier than the current ~six-month detection window. The company plans further research to confirm breath markers and explore a proprietary device that could detect multiple conditions via a single breath analysis.